Abstract
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have